Additionally, SSRI treatment predominantly targeted the effector/proliferating CD8 T subset, unlike anti-PD-1 treatment, which primarily sustains progenitor exhausted tumor-infiltrating CD8 T cells (Figures 2 and S2). Here, CD8A is linked to neoplasm.